NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

Thanks, biosectinvestor:



biosectinvestor Member Level Sunday, 01/30/22 11:56:37 AM
Re: ae kusterer post# 439768 0
Post #
439775
of 439783
I don’t think I was on the cutting edge of discovering Stupp’s change. But if you ask me I believe it would be a conflict to continue advising NVCR while taking a gig with NWBO and apparently he saw a better opportunity to be involved with NWBO at this time. Not sure it is anything more than that.

As for his likely work, I think it would primarily be around ensuring that the synthetic placebo arm is seen as valid and not an issue. That would be his strongest role and he would also be isolated from the group reviewing the unblinded trial results in my opinion, if he performed that role. He created the standard of care, so having him create the synthetic placebo characterizing the standard of care makes the most sense to me.



ae kusterer Sunday, 01/30/22 10:55:43 AM
Re: biosectinvestor post# 439763 0
Post #
439768
of 439784

Biosectinvestor: Since you were on the cutting edge with the 1/22/22 dicovery of Stupp's advisory role at Nwbo, could you please comment on the timing supposition note below? Thank You.A.E.K.



ae kusterer Saturday, 01/29/22 07:40:59 PM
Re: None 0
Post #
439701
of 439766
Question: Between 3/21 and 10/21,what caused Stupp to switch as an advisor from NVCR to NWBO ? If the final draft of Liau’s paper was submitted to the Journal about 11/5/21, was Stupp’s head turned by reading an earlier draft ?

(this Stupp presentation emerged 1/9/22.It took place 10/21) ( Stupp in this slide-deck reveals he is an advisor to NWBO) )

(Stupp pro TTF March, ’21) (probably an advisor to NVCR then )